ABBOTT PARK, Ill., Aug. 29, 2022 /PRNewswire/ -- Abbott today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least ...
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk ...
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the ...
An Abbott recall concerns more than 1,500 of the tablet apps used to communicate with and control its implanted long-term heart pumps, after reports that software issues could cause the pumps to stop ...
Hundreds of HeartMate 3 left ventricular assist device (LVAD) systems are being recalled due to reports of blood leakage or air entering the seal interface between the device inflow cannula and the ...
Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...
Fourteen people have died and 273 have been injured as a result of biological material building up over time in the grafts connecting both HeartMate II and HeartMate 3 left ventricular assist device ...
Sometimes little things can create big problems, which seems to be the case with the recall of the power unit used with the Abbott Heartmate 3 left ventricular assist device (LVAD). According to the ...
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients About Cadrenal Therapeutics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results